Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus.

Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W.

J Neurooncol. 2018 Aug 7. doi: 10.1007/s11060-018-2969-3. [Epub ahead of print]

PMID:
30088191
2.

Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.

McCall NS, Simone BA, Mehta M, Zhan T, Ko K, Nowak-Choi K, Rese A, Venkataraman C, Andrews DW, Anne' PR, Dicker AP, Shi W, Simone NL.

Breast Cancer Res Treat. 2018 Jul 18. doi: 10.1007/s10549-018-4880-1. [Epub ahead of print]

PMID:
30022328
3.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

PMID:
29760221
4.

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.

Du S, McCall N, Park K, Guan Q, Fontina P, Ertel A, Zhan T, Dicker AP, Lu B.

Oncoimmunology. 2018 Jan 29;7(4):e1408747. doi: 10.1080/2162402X.2017.1408747. eCollection 2018.

5.

Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.

Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, Rafiq K, Dicker AP, Knudsen KE, Shoyele SA, Den RB.

Mol Pharm. 2018 May 7;15(5):1778-1790. doi: 10.1021/acs.molpharmaceut.7b01024. Epub 2018 Apr 4.

PMID:
29616555
6.

The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.

Arnold KM, Flynn NJ, Raben A, Romak L, Yu Y, Dicker AP, Mourtada F, Sims-Mourtada J.

Cancer Growth Metastasis. 2018 Mar 9;11:1179064418761639. doi: 10.1177/1179064418761639. eCollection 2018. Review.

7.

Utilizing 10-Year Results From the American Board of Radiology Clinical Examination to Identify Areas for Programmatic Improvement.

Den RB, Folino M, Dicker AP.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):556-557. doi: 10.1016/j.ijrobp.2017.11.032. Epub 2017 Nov 27. No abstract available.

PMID:
29413270
8.

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.

McCall NS, Dicker AP, Lu B.

Clin Cancer Res. 2018 Mar 15;24(6):1271-1276. doi: 10.1158/1078-0432.CCR-17-3269. Epub 2018 Jan 22.

PMID:
29358503
9.

Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.

Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, Birbe R, Salvino JM, Dicker AP, Knudsen KE, Den RB.

Clin Cancer Res. 2018 Mar 15;24(6):1402-1414. doi: 10.1158/1078-0432.CCR-17-2074. Epub 2018 Jan 8.

PMID:
29311118
10.

PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes.

Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N, Zaorsky NG, Ma X, Wang Y, Dicker AP, Lu B.

J Thorac Oncol. 2018 Apr;13(4):510-520. doi: 10.1016/j.jtho.2017.12.002. Epub 2017 Dec 13.

PMID:
29247829
11.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

12.

Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.

Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW.

Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.

PMID:
29233664
13.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
14.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators.

Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28.

PMID:
29183960
15.

Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.

Lawrence YR, Moughan J, Magliocco AM, Klimowicz AC, Regine WF, Mowat RB, DiPetrillo TA, Small W Jr, Simko JP, Golan T, Winter KA, Guha C, Crane CH, Dicker AP.

Cancer. 2018 Feb 1;124(3):491-498. doi: 10.1002/cncr.31058. Epub 2017 Oct 20.

PMID:
29053185
16.

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases.

Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):22-30. doi: 10.1016/j.ijrobp.2017.05.028. Epub 2017 May 26.

PMID:
28816150
17.

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.

Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH.

JAMA Oncol. 2017 Nov 1;3(11):1520-1528. doi: 10.1001/jamaoncol.2017.1598.

18.

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839.

Edelman MJ, Hu C, Le QT, Donington JS, D'Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, Bradley JD.

J Thorac Oncol. 2017 Sep;12(9):1413-1420. doi: 10.1016/j.jtho.2017.06.007. Epub 2017 Jun 16.

PMID:
28629896
19.

mHealth: Mobile Technologies to Virtually Bring the Patient Into an Oncology Practice.

Pennell NA, Dicker AP, Tran C, Jim HSL, Schwartz DL, Stepanski EJ.

Am Soc Clin Oncol Educ Book. 2017;37:144-154. doi: 10.14694/EDBK_176093.

20.

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY.

J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30. Review.

PMID:
28358655
21.

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.

Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F.

J Clin Oncol. 2017 Jun 20;35(18):1982-1990. doi: 10.1200/JCO.2016.69.9918. Epub 2017 Mar 28.

PMID:
28350520
22.

IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling.

Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shyr Y, Dicker AP, Lu B.

Mol Cancer Res. 2017 Jul;15(7):896-904. doi: 10.1158/1541-7786.MCR-16-0390. Epub 2017 Mar 22.

23.

Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics.

Kim H, Malatesta TM, Anné PR, McAna J, Bar-Ad V, Dicker AP, Den RB.

Pract Radiat Oncol. 2017 Jul - Aug;7(4):241-245. doi: 10.1016/j.prro.2016.12.003. Epub 2016 Dec 16.

PMID:
28132850
24.

Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.

Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN.

Clin Genitourin Cancer. 2017 Jun;15(3):e299-e309. doi: 10.1016/j.clgc.2016.08.012. Epub 2016 Aug 17.

PMID:
28089723
25.

RB Loss Promotes Prostate Cancer Metastasis.

Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB.

Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.

26.

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.

J Clin Oncol. 2017 Jan 10;35(2):139-140. Epub 2016 Nov 28. No abstract available.

27.

Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY.

Lancet Oncol. 2016 Nov;17(11):1612-1620. doi: 10.1016/S1470-2045(16)30491-0. Epub 2016 Oct 12.

PMID:
27743920
28.

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.

Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB.

Urol Case Rep. 2016 Oct 1;9:51-54. eCollection 2016 Nov.

29.

Stereotactic Body Radiation Therapy Delivery in a Genetically Engineered Mouse Model of Lung Cancer.

Du S, Lockamy V, Zhou L, Xue C, LeBlanc J, Glenn S, Shukla G, Yu Y, Dicker AP, Leeper DB, Lu Y, Lu B.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):529-37. doi: 10.1016/j.ijrobp.2016.07.008. Epub 2016 Jul 21.

30.

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.

Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, Lu B.

J Hematol Oncol. 2016 Sep 23;9(1):96.

31.

Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.

Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE.

J Urol. 2017 Jan;197(1):122-128. doi: 10.1016/j.juro.2016.08.091. Epub 2016 Aug 26.

PMID:
27569435
32.

β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation.

Sayeed A, Lu H, Liu Q, Deming D 2nd, Duffy A, McCue P, Dicker AP, Davis RJ, Gabrilovich D, Rodeck U, Altieri DC, Languino LR.

Oncotarget. 2016 Aug 16;7(33):52618-52630. doi: 10.18632/oncotarget.10522.

33.

Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study.

Myers RE, Leader AE, Censits JH, Trabulsi EJ, Keith SW, Petrich AM, Quinn AM, Den RB, Hurwitz MD, Lallas CD, Hegarty SE, Dicker AP, Zeigler-Johnson CM, Giri VN, Ayaz H, Gomella LG.

J Cancer Educ. 2018 Feb;33(1):180-185. doi: 10.1007/s13187-016-1073-7.

PMID:
27418065
34.

Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.

Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS.

Am J Clin Oncol. 2018 May;41(5):441-446. doi: 10.1097/COC.0000000000000317.

PMID:
27391356
35.

The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer.

Zaorsky NG, Egleston BL, Horwitz EM, Dicker AP, Nguyen PL, Showalter TN, Den RB.

Am J Clin Oncol. 2016 Aug;39(4):321-6. doi: 10.1097/COC.0000000000000313.

PMID:
27322694
36.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.

PMID:
27247218
37.

Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.

Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):277-82. doi: 10.1038/pcan.2016.15. Epub 2016 May 3.

38.

Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.

Zaorsky NG, Keith SW, Shaikh T, Nguyen PL, Horwitz EM, Dicker AP, Den RB.

Am J Clin Oncol. 2018 Apr;41(4):409-415. doi: 10.1097/COC.0000000000000285.

PMID:
27014930
39.

Plan Quality and Treatment Efficiency for Radiosurgery to Multiple Brain Metastases: Non-Coplanar RapidArc vs. Gamma Knife.

Liu H, Andrews DW, Evans JJ, Werner-Wasik M, Yu Y, Dicker AP, Shi W.

Front Oncol. 2016 Feb 11;6:26. doi: 10.3389/fonc.2016.00026. eCollection 2016.

40.

Quality and Reporting Accuracy of Phase 1 Drug Radiation Clinical Trials.

Kim H, Dan TD, Palmer JD, Leiby BE, Lawrence YR, Dicker AP.

JAMA Oncol. 2016 Mar;2(3):390-1. doi: 10.1001/jamaoncol.2015.4833. No abstract available.

PMID:
26841256
41.

Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.

Shi W, Palmer JD, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L, Bar-Ad V, Judy K, Farrell C, Simone N, Liu H, Dicker AP, Lawrence YR.

J Neurooncol. 2016 May;127(3):535-9. doi: 10.1007/s11060-016-2059-3. Epub 2016 Jan 29.

PMID:
26821711
42.

Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.

Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB.

Eur Urol. 2016 Oct;70(4):588-596. doi: 10.1016/j.eururo.2016.01.008. Epub 2016 Jan 21.

43.

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.

Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY.

JAMA Oncol. 2016 Apr;2(4):471-80. doi: 10.1001/jamaoncol.2015.4955.

44.

A single activity with a practice quality improvement project for faculty and a quality improvement project for residents.

Kim H, Malatesta TM, Simone NL, Den RB, McAna J, Dicker AP, Bar Ad V.

Pract Radiat Oncol. 2016 Mar-Apr;6(2):114-8. doi: 10.1016/j.prro.2015.10.014. Epub 2015 Oct 28.

PMID:
26723550
45.

The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.

Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY.

Clin Cancer Res. 2016 Apr 1;22(7):1777-86. doi: 10.1158/1078-0432.CCR-15-1250. Epub 2015 Dec 2.

46.

CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement.

Shi W, Dicker AP.

J Clin Oncol. 2016 Jan 10;34(2):107-9. doi: 10.1200/JCO.2015.63.9682. Epub 2015 Nov 30. No abstract available.

PMID:
26628475
47.

Evaluating the quality, clinical relevance, and resident perception of the radiation oncology in-training examination: A national survey.

Kim H, Bar Ad V, McAna J, Dicker AP.

Pract Radiat Oncol. 2016 Jan-Feb;6(1):44-9. doi: 10.1016/j.prro.2015.09.013. Epub 2015 Nov 11.

PMID:
26577011
48.

Social Media and Oncology: The Past, Present, and Future of Electronic Communication Between Physician and Patient.

Lewis MA, Dicker AP.

Semin Oncol. 2015 Oct;42(5):764-71. doi: 10.1053/j.seminoncol.2015.07.005. Epub 2015 Jul 10. Review.

49.

RO-ILS: Radiation Oncology Incident Learning System: A report from the first year of experience.

Hoopes DJ, Dicker AP, Eads NL, Ezzell GA, Fraass BA, Kwiatkowski TM, Lash K, Patton GA, Piotrowski T, Tomlinson C, Ford EC.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):312-318. doi: 10.1016/j.prro.2015.06.009. Epub 2015 Jun 25.

PMID:
26362705
50.

Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM.

J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20.

Supplemental Content

Loading ...
Support Center